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In Vivo Measurement of Brain GABA Concentrations by
Magnetic Resonance Spectroscopy in Smelters Occupationally
Exposed to Manganese
Abstract
Background: Exposure to excessive manganese (Mn) levels is known to induce psychiatric and motor
disorders including parkinsonian symptoms. Therefore finding a reliable means for early detection of
Mn neurotoxicity is desirable. Objectives: Our goal was to study whether in-vivo brain levels of
gamma-aminobutyric acid (GABA), N-acetylaspartate (NAA) and other brain metabolites in smelters
were altered as a consequence of Mn exposure. Methods: T1-weighted MRI was used to visualize Mn
deposition in the brain. Magnetic resonance spectroscopy (MRS) was used to quantify concentrations of
NAA, glutamate and other brain metabolites in globus pallidus, putamen, thalamus, and frontal cortex
from a well-established cohort of 10 male Mn-exposed smelters and 10 male age-matched control
subjects. The MEGA-PRESS MRS sequence was used to determine GABA levels in a region
encompassing the thalamus and adjacent parts of the basal ganglia ("GABA-VOI"). Results: Seven out
of ten exposed subjects showed clear T1-hyperintense signals in the globus pallidus indicating Mn
accumulation. We found a significant increase (82%; p=0.014) of GABA/tCr in the GABA-VOI of
Mn-exposed subjects, as well as a distinct decrease (9%, p=0.04) of NAA/tCr in frontal cortex that
strongly correlated (R= - 0.93, p<0.001) with cumulative Mn exposure. Conclusions: We demonstrated
elevated GABA levels in the thalamus and adjacent basal ganglia and decreased frontal cortex NAA
levels, indicating neuronal dysfunction in a brain area not primarily targeted by Mn. Therefore, the
non-invasive in vivo MRS measurement of GABA and NAA may prove to be a powerful tool for
detecting presymptomatic effects of Mn neurotoxicity.
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Abbreviations and Definitions:
Cho Choline-containing compounds   
GABA Gamma-Aminobutyric Acid 
GABA+ GABA plus co-edited macromolecules 
Glu Glutamate 
Gln Glutamine 
Glx the sum of Glu and Gln 
GM Grey matter  
mI Myo-Inositol 
MM Macromolecule  
Mn Manganese 
MRI Magnetic Resonance Imaging 
MRS Magnetic Resonance Spectroscopy 
NAA N-Acetyl Aspartate 
PD Parkinson’s Disease 
PI Pallidal Index with WM as reference 
ROI Region of interest 
tCr total creatine 
TE Echo time 
TR Repetition time 
VOI Volume of interest 
WM White matter 
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Abstract  
Background: Exposure to excessive manganese (Mn) levels is known to induce psychiatric and motor 
disorders including parkinsonian symptoms.  Therefore finding a reliable means for early detection of Mn 
neurotoxicity is desirable. 
Objectives: Our goal was to study whether in-vivo brain levels of gamma-aminobutyric acid (GABA), N-
acetylaspartate (NAA) and other brain metabolites in smelters were altered as a consequence of Mn 
exposure. 
Methods:  T1-weighted MRI was used to visualize Mn deposition in the brain. Magnetic resonance 
spectroscopy (MRS) was used to quantify concentrations of NAA, glutamate and other brain metabolites 
in globus pallidus, putamen, thalamus, and frontal cortex from a well-established cohort of 10 male Mn-
exposed smelters and 10 male age-matched control subjects. The MEGA-PRESS MRS sequence was 
used to determine GABA levels in a region encompassing the thalamus and adjacent parts of the basal 
ganglia (“GABA-VOI”).  
Results: Seven out of ten exposed subjects showed clear T1-hyperintense signals in the globus pallidus 
indicating Mn accumulation. We found a significant increase (82%; p=0.014) of GABA/tCr in the 
GABA-VOI of Mn-exposed subjects, as well as a distinct decrease (9%, p=0.04) of NAA/tCr in frontal 
cortex that strongly correlated (R= - 0.93, p<0.001) with cumulative Mn exposure.  
Conclusions: We demonstrated elevated GABA levels in the thalamus and adjacent basal ganglia and 
decreased frontal cortex NAA levels, indicating neuronal dysfunction in a brain area not primarily 
targeted by Mn. Therefore, the non-invasive in vivo MRS measurement of GABA and NAA may prove to 
be a powerful tool for detecting presymptomatic effects of Mn neurotoxicity. 
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Introduction 
Manganese (Mn) is an essential trace element important for neuronal function; however, excessive 
exposure to Mn has been associated with a severe movement disorder known as manganism. The clinical 
manifestations of Mn poisoning pertain to an extrapyramidal syndrome, with a pattern similar, but not 
identical to Parkinson’s disease (PD). The signs and symptoms frequently include action tremor with 
absence or low level of resting tremor, hypertonia and adiadochokinesia. In severe cases, gait disturbance 
is observed. Furthermore, Mn neurotoxicity has been linked to distorted mental function, including 
memory loss, apathy, and even psychosis (Aschner et al. 2007; Calne et al. 1994; Crossgrove and Zheng 
2004; Jiang et al. 2006). Occupational exposure to Mn, such as from ore extraction and processing, steel 
and alloy production, welding, chemical synthesis, ceramic production and dry-battery fabrication, is a 
common source of Mn poisoning. Since Mn-induced neurotoxicity is an important occupational health 
risk, there is an urgent demand for establishing effective techniques for early diagnosis of manganism. We 
hypothesize that pathogenic markers of Mn neurotoxicity reflecting metabolic or excitotoxic insults, such 
as changes in neurotransmitter levels or other brain metabolites, likely occur before structural damage. 
Mn is known to accumulate most prominently in the globus pallidus (Dorman et al. 2006; Guilarte 
et al. 2006a; Jiang et al. 2007).  It can be visualized by increased signal intensity in the globus pallidus of 
occupationally exposed workers in T1-weighted magnetic resonance imaging (MRI) (Dietz et al. 2001; 
Jiang et al. 2007; Kim et al. 1999; Lucchini et al. 2000; Nelson et al. 1993). A common approach to 
quantifying this change in signal contrast is the definition of the pallidal index (PI), defined as the ratio 
between the signal intensity within the globus pallidus and a control region, commonly chosen as 
subcortical frontal white matter (Krieger et al. 1995). However, brain regions outside the basal ganglia, 
such as frontal cortex, have also been reported to be affected by Mn and to exhibit neurodegenerative 
changes (Guilarte et al. 2008). 
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To investigate the effects of Mn on brain chemistry, we used magnetic resonance spectroscopy 
(MRS) to measure the concentrations of metabolites, such as N-acetylaspartate (NAA, a marker of general 
neuronal function), total creatine (tCr, involved in energy metabolism), choline-containing compounds 
(Cho, an indicator of cell membrane integrity), myo-inositol (mI, a glial cell marker) and glutamate (Glu, 
an excitatory neurotransmitter). Furthermore, MEGA-PRESS (Mescher et al. 1998), a special MRS 
editing technique, allows for enhanced assessment of the small resonances of gamma-aminobutyric acid 
(GABA) (Edden and Barker 2007). 
Several in vitro and in vivo rodent studies have linked increased Mn exposure to alterations in 
concentrations as well as the metabolism of neurotransmitters, in particular dopamine, GABA and Glu 
(Burton and Guilarte 2009).  Findings of GABAergic alterations are conflicting. Early in vitro studies 
reported increased striatal GABA levels in Mn-exposed rodents (Bonilla 1978; Gianutsos and Murray 
1982); these are supported by later work that correlates Mn exposure with increased brain GABA 
concentrations (Gwiazda et al. 2002; Lipe et al. 1999; Reaney et al. 2006). Other groups, however, have 
failed to corroborate these studies, reporting decreased GABA levels upon Mn exposure (Brouillet et al. 
1993; Chandra et al. 1982; Erikson et al. 2002; Seth et al. 1981) or no association between GABA levels 
and Mn exposure (Bonilla et al. 1994). 
In non-human primates with high exposure to Mn, Guilarte et al. (2006b) found an intact but 
dysfunctional nigrostriatal dopaminergic system. Subsequent studies in non-human primates found no 
evidence that chronic Mn exposure alters total levels of dopamine, Glu or GABA (Burton et al. 2009; 
Struve et al. 2007). In contrast, in postmortem tissue studies, elevated GABA levels in PD are well 
established. For example, Kish et al. (1987) reported above-normal GABA levels in the PD striatum, 
especially in the posterior putamen, which correlated inversely with reduced dopamine levels. 
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The current study, to our knowledge, is the first to investigate the effect of Mn exposure on GABA 
concentrations in the living human brain. Our objectives were as follows: (1) determine the concentrations 
of active metabolites like NAA (a neuronal marker) in selected brain regions of Mn-exposed subjects 
compared to a control group, (2) determine whether chronic Mn exposure in humans alters GABA levels, 
and (3) correlate all of the MRS parameters and the PI as measured by MRI to external indices of Mn 
exposure, such as cumulative Mn exposure. 
 
Materials and Methods 
Subjects, Air Sampling and Physiological Tests 
Twenty male subjects were recruited out of a large, well-studied cohort of workers from a Mn-Fe alloy 
manufactory in Zunyi, China. The average airborne MnO2 concentration in the current daily working 
environment of both the exposed and the control group was determined in a previous study (see Cowan et 
al. 2009 for the detailed air sampling procedure and data). Air samples were collected over more than 10 
working shifts on three consecutive days for each work environment. Since Cowan’s study, the working 
conditions have not changed for the subjects in this report. The working history and medical history of all 
subjects were available from the same study. A group of 10 Mn-exposed smelters (mean age = 40.7 years, 
average airborne MnO2 = 0.18 mg/m3, mean years of occupational exposure = 7.8 years), exposed on a 
daily basis at the time of the MRI study, and 10 male age-matched control subjects with no history of Mn 
exposure (mean age = 43.4 years, mean airborne Mn exposure = 0.003 mg/m3) were chosen for the MRI 
and MRS study. The “cumulative Mn concentration” was defined as the product of average airborne 
MnO2 concentration of each group times years of occupational exposure times volume of inhaled air. 
Written informed consent was obtained from each subject prior to participation, and the study was 
approved by Institutional Review Boards both in China and the U.S. 
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 The twenty subjects were brought to the 1st Affiliated Hospital of Guangxi Medical University on 
a weekend day, where urine and blood tests, as well as neurological and physiological tests were 
performed directly prior to the MRI examination. In particular Mn, iron (Fe) and copper (Cu) levels were 
measured in urine, blood plasma and red blood cells, and pulse rate and blood pressure were determined. 
All subjects were evaluated by a neurologist (XM) who specializes in PD for clinical manifestation of 
manganism, following clinical assessment tests for PD (tremor, rigidity, bradykinesia and postural 
instability) using the motor exam tests suggested by the Unified Parkinson’s Diseases Rating Scale 
(UPDRS) Development Team (Fahn et al. 1987). Since no symptoms were identified in any of the study 
participants, the UPDRS scoring was not performed in this study.  
MRI and Image Analysis 
All MRI measurements were performed on a 3T Philips Achieva whole body clinical scanner (Philips 
Healthcare, The Netherlands), equipped with an 8-channel head coil. Fast T2-weighted images were 
acquired in all three orientations for exact planning of the spectroscopy volumes of interest (VOIs) and for 
delineation of the globus pallidus, which shows up dark in T2-weighted images due to its high iron 
content. A high-resolution (1mm x 1mm x 1.5 mm pixel) T1-weighted 3-dimensional fast gradient echo 
scan (repetition time TR = 9.7 ms, echo time TE = 4.6 ms, 120 slices, Field of View = 240 x 240 x 150 
mm3, SENSE factor 2) covering the whole head was acquired for image segmentation and for detailed 
analysis of the areas showing hyperintensities due to Mn deposition in the brain. The resulting 3D T1-
weighted images were reconstructed in all 3 dimensions and inspected for hyperintense signal in the basal 
ganglia (Figure 1). These images were also used to calculate the pallidal index (PI) based on the signal 
ratio between a ROI within the globus pallidus and a ROI from white matter in the frontal lobe.  
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MRS, GABA Editing and Spectral Data Analysis 
In addition to imaging, short-echo-time single voxel spectra (PRESS localization, TR/TE = 1500ms/30ms, 
CHESS water suppression) were acquired from 5 different volumes of interest (VOIs) in each subject: 
frontal cortex (8 ml VOI, 96 averages), putamen (4 ml VOI, 128 averages), globus pallidus (4.5 ml VOI, 
176 averages), thalamus (4.5 ml VOI, 128 averages) and a larger voxel, the “GABA-VOI”, centered on 
the thalamus, but also containing the posterior parts of the putamen and globus pallidus, as well as parts 
of the substantia nigra (26.25 ml, 32 averages) (Supplemental Material, Figure 1). The location of the five 
VOIs can be seen in Figure 2. For each voxel, a reference spectrum was acquired without water 
suppression that was later used for phase and frequency correction of the corresponding water-suppressed 
spectrum. Shimming and other preparation phases were performed fully automatically, resulting in 
linewidths of < 10 Hz for the unsuppressed water peak for all spectra. 
The larger volume of the GABA-VOI was necessary for the detection of GABA concentrations on 
the order of 1 mM. The current state-of-the-art technique to detect metabolites such as GABA, whose 
MRS peaks are overshadowed by much larger peaks in conventional MRS, is the homonuclear MEGA-
PRESS J-editing sequence (Mescher et al. 1998). This technique, when adapted for GABA (Edden and 
Barker 2007; Waddell et al. 2007), eliminates most of the overlapping signal and allows for much more 
accurate detection of GABA. (For a detailed description of the MEGA-PRESS technique and subsequent 
processing, see the Supplemental Material.) MEGA-PRESS optimized for GABA detection (TR = 2000 
ms, TE = 68 ms) has been validated in several clinical studies (e.g., Bhagwagar et al. 2007; Edden et al. 
2009; Öz et al. 2006; Tayoshi et al. 2010) and was included in this study in addition to the short TE single 
voxel scans to investigate changes in GABA concentrations. 256 averages were acquired, half with the 
MEGA-PRESS editing pulse centered at 1.9 ppm, half with the pulse centered at 7.6 ppm in an 
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interleaved fashion. See Supplemental Material, Figure 2, for a representative GABA-edited spectrum 
compared to the short TE spectrum from the same VOI.  
All MRS data processing was performed with LCModel (Provencher 1993), a spectral 
quantification tool that fits each spectrum as a weighted linear combination of basis spectra from 
individual brain metabolites. LCModel also provides an estimated relative standard deviation (%SD) for 
each metabolite as a measure of the believability of the concentration values reported. It has recently been 
used with MEGA-PRESS to measure GABA concentrations in schizophrenics (Tayoshi et al. 2010) and 
in depressed and bipolar subjects (Bhagwagar et al. 2007). For the short-echo-time data, a basis set of in 
vitro spectra from individual metabolite solutions was used, and only fitting results with relative standard 
deviations (%SD) < 25% were used for further statistical analysis.  For the MEGA-PRESS spectra, basis 
sets were generated from density matrix simulations of the sequence using published values for chemical 
shifts and J-couplings (Govindaraju et al. 2000). The difference basis set included GABA, Glu, glutamine, 
glutathione and NAA. 
A known issue with estimating GABA concentrations from difference spectra is the presence of 
co-edited macromolecule (MM) signal at 3.0 ppm – a broad signal that underlies the GABA resonance at 
this frequency, creating a potential source of error. Two different approaches were used to model its effect 
and obtain GABA concentrations, yielding estimates for upper and lower limits on the “true” GABA 
concentration. For Method 1, the potential confound of a macromolecule signal at 3.0 ppm was not 
explicitly included in the LCModel processing (as in Tayoshi et al. 2010). The resulting LCModel fits 
have satisfyingly small relative standard deviation values (%SD) for GABA, but the concentrations are 
probably overestimated. For Method 2, an extra Gaussian peak at 3.0 ppm (“MM30”) was added to the 
LCModel calculation to explicitly fit the macromolecular signal (a simpler version of the technique used 
by Bhagwagar et al. 2007). 
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For all spectra (PRESS as well as MEGA-PRESS), metabolite levels were expressed as a ratio to 
total creatine (tCr). In the case of the GABA-edited spectra, the reference values for tCr were taken from 
the average of the OFF spectra (with the MEGA-PRESS pulse centered at 7.6 ppm and thus not affecting 
tCr). 
Statistics 
All data were expressed as mean ± S.D. Comparison of means between Mn-exposed and control 
groups was performed with a two-tailed Student t-test with Welch correction for unequal variances. 
Correlation analysis was conducted and Spearman coefficients were obtained accordingly using 
SPSS/PC+ for Windows (V. 13.0).  
 
Results 
No study participant showed clinical symptoms or signs of PD or manganism in any of the tests 
performed. All 20 subjects were able to finish the full study and all imaging and spectroscopy data 
acquired were of adequate quality to be included in the analysis. Of the various internal exposure 
parameters (Fe, Mn, and Cu in blood and urine), only Cu in urine showed a significant group difference 
between the smelters and the control group (p = 0.013), with the smelters having higher levels.  (All other 
measures had group difference p values > 0.1; see Supplemental Material, Table 1).  
MRI and Pallidal Index (PI) 
Seven out of ten exposed subjects showed a clearly hyperintense signal in the 3D T1-weighted 
images, revealing Mn deposition in the brain. As illustrated in Figure 1, the T1 shortening caused by Mn 
deposition was most prevalent in the globus pallidus and adjacent brain regions. 
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As expected, a significant group difference between the exposed and non-exposed subjects was 
identified for the PI (p = 0.007). However, no cut-off value could be established to classify subjects 
exclusively to the exposed or non-exposed group using the PI. For example, if a cut-off value of 1.2 is 
chosen, seven exposed subjects are correctly identified and only one control is wrongly identified as a 
Mn-exposed worker, as illustrated in Fig. 1c.  
Short TE MRS 
Spectral data quality was high (linewidth < 10 Hz, no artifacts) in all 120 short TE spectra from 
the five brain locations acquired in this study. Typical spectra from each VOI are shown in Figure 2. 
Table 1 lists the ratios with respect to total creatine of NAA, Cho, mI, Glu and Glx (= Glu + Gln) as 
reported by LCModel from the exposed and non-exposed subjects. The only significant group difference 
was found in the frontal cortex: NAA/tCr was significantly lower in the exposed group than in the control 
group (p=0.04) (Fig. 3b) and the value decreased as the cumulative Mn exposure increased (R= -.93, 
p<0.001 for the Mn-exposed group alone, R=-.75, p<0.001 for all subjects) (Fig. 3c). While there 
appeared to be a trend for a decrease in NAA/tCr in the globus pallidus of the exposed group, this 
decrease was not statistically significant, as five out of 20 NAA results from these inherently broader 
spectra had %SD values from LCModel ≥ 25% and were thus excluded from the calculation. No NAA 
changes, i.e., group differences or correlation to other internal or external parameters of exposure indices 
were found in thalamus or putamen, nor were the levels of other metabolites (Cho, mI, Glu or Glx) 
significantly altered in any of the examined brain areas.  
 
GABA MRS 
Figure 2g shows the LCModel fit of a GABA-edited spectrum from the 26 ml VOI centered on the 
thalamus (GABA-VOI). LCModel results for GABA/tCr from the MEGA-PRESS spectra are 
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summarized in Table 1 for both Method 1 (GABA fit without explicit consideration of macromolecules at 
3.0 ppm) and Method 2 (processing that included an extra macromolecular peak at 3.0 ppm). For both 
methods, a Student t-test revealed a statistically significant difference (p < 0.05) between the Mn-exposed 
and control subjects for the raw GABA signal and GABA/tCr.  The average GABA concentration was    
~50% higher in Mn-exposed workers than in controls using Method 1, and it was ~80% higher using 
Method 2. Estimates for GABA concentrations from Method 1, assuming [tCr] = 6.0 mM in the thalamus 
(Geurts et al. 2004), were 1.32 mM for the Mn-exposed group and 0.90 mM for the controls. With an 
MM30 model peak added in Method 2, the average GABA concentration was reduced to 0.62 mM for the 
Mn-exposed group and to 0.34 mM for the controls (Fig. 3a).  
In contrast to the marked difference in GABA values between Mn-exposed and control workers, 
the LCModel results for the MM30 peak in Method 2 were consistent for all subjects, suggesting that 
macromolecule levels are not appreciably altered by Mn exposure. The same consistency was seen in the 
MEGA-PRESS glutamate results (data not shown).   
 
Discussion 
The nature of the involvement of GABA and Glu in Mn neurotoxicity remains unknown. This study, for 
the first time, employs a noninvasive MRI/MRS technique to quantify the GABA and Glu concentrations 
in the living brain of smelters exposed to airborne Mn in an occupational environment. Based on the data 
acquired, we observed that brain GABA levels are significantly increased in these workers versus 
matched controls in a brain volume encompassing the thalamus and parts of the basal ganglia, such as the 
posterior putamen and posterior parts of the globus pallidus. Furthermore, NAA levels in the frontal 
cortex decrease as a function of cumulative Mn exposure. Although none of the examined subjects 
showed any clinical symptoms of parkinsonism or motor deficits, the dramatically increased GABA 
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levels in the thalamus and basal ganglia together with the decreased NAA levels in the frontal cortex 
likely reflect early metabolic or possibly pathologic changes of Mn exposure.  
While the effect of Mn exposure on the GABAergic system has been investigated both in vitro and 
in vivo on rodent models, the results are contradictory. In non-human primate models, no changes in 
GABA were found (Burton et al. 2009; Struve et al. 2007). Notably, all of these studies have assessed 
GABA levels in cultures or ex vivo. The differences in Mn exposure paradigms, temporal relations or 
species, as well as the differences in the methods used for GABA quantification, may account for the 
large variations in these findings. In the current study, we used the MEGA-PRESS MRS technique, which 
allows for the specific detection of the small GABA MRS signal in vivo. Although MEGA-PRESS has 
been used for human studies by other groups (e.g. Bhagwagar et al. 2007; Edden et al. 2009, Tayoshi et 
al. 2010), quantification of GABA is not straightforward or well established. It is known that signal from 
co-edited macromolecules contributes to the GABA peak at 3.0 ppm in the edited spectra, but since it is 
not trivial to eliminate this source of error completely, often only “GABA+” (= GABA + co-edited 
moieties) is reported. For this study, we used a more accurate approach and fitted all of the GABA 
resonances in the spectrum using prior knowledge of the exact spin evolution and spectral signature of the 
GABA multiplets for the MEGA-PRESS sequence, and we compared two processing schemes: relying on 
the LCModel baseline function to handle the MM contribution at 3.0 ppm (Method 1) versus including a 
new separate MM peak in the fit (Method 2). Consistently small p values strongly suggest that GABA is 
indeed increased in the basal ganglia of Mn-exposed subjects. GABA concentrations obtained from 
Method 2 were reduced by roughly a factor of two relative to Method 1, in agreement with reports that the 
contribution of the macromolecular signal is about 50% of the total signal at 3.0 ppm (Hetherington et al. 
1998; Rothman et al. 1993). 
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Although the mean airborne Mn level for the exposed smelters was only 0.18 mg/m3, which is 
slightly below the American Conference of Governmental Industrial Hygienists (ACGIH) Threshold 
Limit Value (TLV) of 0.2 mg/m3, we observed nearly doubled GABA concentrations in the Mn-exposed 
smelters in a region encompassing mainly the thalamus, but also the posterior part of the putamen and of 
the globus pallidus. The mechanisms associated with changes in GABA levels that are inherent to chronic 
Mn exposure are presently unknown. The observed increases in GABA levels corroborate observations by 
others of high GABA concentrations in the striatum of PD patients ex vivo (Hornykiewicz 2001; Kish et 
al. 1987) and increases in striatal GABA levels  in animal models of PD, such as 6-OHDA (Bruet et al. 
2003; Lindefors 1993). Changes in GABAergic neurotransmission in PD patients and 6-OHDA rats 
suggest that PD motor sign expression may depend on increases in striatal GABAergic neurotransmission.  
Striatal GABA originates from two distinct populations of neurons: medium spiny neurons expressing 
local and close axonal collaterals and interneurons that strongly inhibit striatal neuron projections (Plenz 
2003). Accordingly, these interneurons seem to generate a strong inhibitory feedback, decreasing striatal 
output activity. While the role of GABA in manganism has yet to be clearly delineated, the observation of 
a Mn-induced increase in thalamic GABA levels among Mn-exposed smelters should prompt additional 
in-depth investigation on the mechanisms associated with this change. As recently suggested by Guilarte 
(2010), Mn-induced motor dysfunction reflects altered mechanisms of presynaptic dopamine release 
rather than its synthesis, and may be distinct from mechanisms associated with PD. Given that dopamine 
homeostasis was not studied in the present cohort of smelters, future studies should systematically address 
the effects of Mn on the dopaminergic system as well to further delineate temporal changes, or lack 
thereof, between GABA and other neurotransmitter systems. In addition, improving the sensitivity of 
GABA-edited MRS to enable the use of smaller volumes is desirable to more precisely pinpoint brain 
locations with altered GABA levels. The finding of no significant changes for any other metabolites in the 
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basal ganglia is consistent with an earlier MRS study performed on Mn-exposed welders by Kim et al. 
(2007). 
While the frontal cortex has not been characterized as a target of Mn neurotoxicity, it has been 
shown that Mn also readily accumulates in this region – although to a lesser degree than in the globus 
pallidus (Bock et al. 2008; Dorman et al. 2006; Guilarte et al. 2008). We found a reduced concentration of 
NAA (a marker of neuronal viability) in the frontal cortex of smelters and an inverse correlation with 
cumulative Mn exposure. These results in humans corroborate the findings of neurodegenerative changes 
in this brain region in Mn-exposed non-human primates (Guilarte et al. 2008), as well as reduced NAA 
levels measured by MRS in the parietal cortex from the same non-human primates (Guilarte et al. 2006a). 
Furthermore, the early phase of Mn intoxication involves psychiatric and cognitive effects that might be 
mediated by the frontal cortex and subcortical structures (Josephs et al. 2005). Notably, NAA/tCr changes 
as a function of cumulative Mn exposure are observable at Mn air levels below the ACGIH limit, 
consistent with early presymptomatic neuronal dysfunction. These findings suggest that measurements of 
cortical NAA levels may prove to be a valuable biomarker of the effect of Mn exposure. 
It should be noted, however, that Chang et al. (2009) studied frontal grey matter in Mn-exposed 
welders using MRS and, contrary to our study, observed no changes in NAA/tCr. Moreover, they found 
significantly reduced mI that correlated with verbal memory score and blood Mn concentrations. No other 
changes in metabolite ratios were seen, however. Although the MRS acquisition method (short-TE 
PRESS sequence at 3T), the location of the frontal cortex VOI, the apparent quality of the MRS data and 
the data analysis technique (LCModel) are very similar between the two studies, it needs to be 
acknowledged that other technical differences could easily account for the differences in results, 
especially for reported changes in metabolite concentrations of only 10-20%, as is the case for the 9% 
drop in NAA reported in our study and for the 20% decrease in mI reported by Chang et al.  
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 Although the hyperintense signal in the globus pallidus is an unambiguous marker for Mn 
exposure in a single subject, not all exposed subjects exhibit such a hyperintense signal. Our earlier study 
found a 78% occurrence of intensified PI in Mn-exposed workers and a 85% occurrence in highly-
exposed workers (Jiang et al. 2007). In the current study, we saw hyperintense signal and thus increased 
PI values in seven out of ten subjects from the exposed group, which is similar to our previous findings 
considering the small sample size (n=10). Interestingly the three subjects not showing any hyperintense 
signal did not stand out by any other measure: years of occupational Mn exposure and cumulative Mn 
exposure in these 3 subjects spanned the full range (1 year, 459 mg; 10 years, 4588 mg and 12 years, 5505 
mg). The mechanism that either protects their brain from Mn accumulation or masks the T1-weighted 
contrast caused by Mn in the brain remains to be explored. GABA concentrations in these three subjects 
varied considerably, from the highest GABA level measured in all subjects to lower values (2.0 mM, 1.2 
mM, and 1.6 mM, using Method 1). 
 
Conclusions 
In conclusion, we present for the first time in vivo quantification of GABA in Mn-exposed 
workers and show a significant, almost two-fold increase in GABA levels compared to control subjects in 
a brain region containing the thalamus and parts of the basal ganglia. The fact that GABA levels seem to 
be largely independent of the MR signal hyperintensity associated with Mn deposition in MR images, as 
well as the finding that NAA decreases with exposure in the frontal cortex, where less Mn accumulates 
than in basal ganglia structures, both support the notion suggested by Burton and Guilarte (2009) that it is 
the intrinsic vulnerability to injury by Mn rather than the amount of accumulated Mn in the brain that 
defines its neurotoxicity. Since elevated GABA levels mirror findings in PD, and decreased NAA levels 
corroborate neurodegenerative changes (or at least neuronal dysfunction) observed in non-human 
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primates, these findings may lead to a novel approach in identifying early presymptomatic pathogenic 
effects of Mn exposure.  Larger sample sizes and longitudinal studies will be needed to further validate 
these results. 
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 Table 1: Metabolite concentration ratios from five brain regions  
 NAA/tCra Cho/tCra   mI/tCra  Glx/tCra  Glu/tCra  GABA/tCrb GABA/tCrb 
      (Method 1) (Method 2) 
 
Brain regions 
 
GABAVOI 
smelters 1.12±0.08 0.30±0.02  0.68±0.09  0.82±0.07  0.78±0.05  0.22±0.06  0.10±0.03   
control subjects    1.12±0.08 0.31±0.02  0.76±0.14  0.82±0.10  0.77±0.10  0.15±0.07  0.06±0.04 
percent change 0          -3.2 -10.5 0        1.3       47  82d 
p-value c       0.028  0.014 
 
Thalamus 
smelters 1.01±0.10 0.28±0.03  0.63±0.13  1.35±0.28  1.01±0.15  
control subjects    1.00±0.15 0.30±0.04  0.61±0.10  1.19±0.35  0.90±0.20  
percent change 1.0          -6.7 3.3 13.5 12.2 
 
Putamen 
smelters 0.71±0.11 0.27±0.04  0.53±0.09  1.79±0.32  1.14±0.17 
control subjects    0.63±0.14 0.26±0.02  0.48±0.07  1.86±0.33  1.18±0.12  
percent change 12.7       3.9 10.4 -3.8 -3.4 
 
Globus pallidus 
smelters 0.75±0.22 0.26±0.03  0.45±0.17  1.35±0.49  1.03±0.22  
control subjects    0.63±0.17 0.24±0.03  0.51±0.10  1.36±0.37 0 0.99±0.24 
percent change 19.1 8.3 -11.8 -0.7 4.0 
 
Frontal cortex 
smelters 1.03±0.11 0.32±0.04  0.93±0.16  1.48±0.32  1.19±0.18  
control subjects    1.13±0.10 0.31±0.02  0.88±0.10  1.54±0.17  1.24±0.17  
percent change -8.9    3.2 5.7 -3.9       -4.0 
p-value c 0.042 
 
   
 
a from short-TE spectra 
b from TE 68 MEGA-PRESS spectra 
c
 p-values were calculated using a two-tailed student t-test 
d
 all percent changes were calculated from ratio values prior to rounding: in this case 0.104 / 0.057 
tCr = total Creatine, NAA = N-Acetylaspartate, mI = myo-inositol, Glu = glutamate, Glx = sum of 
glutamate and glutamine 
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Figure legends 
Figure 1: a) Representative axial, coronal and sagittal T1-weighted MR brain images of a subject from the 
Mn-exposed group, depicting the hyperintense signal associated with brain Mn deposition. b) Regions of 
interest (ROIs) used for the determination of the pallidal index. c) Distribution of the PI values for all ten 
exposed subjects and all ten control subjects.  
 
Figure 2: a) Volume of interest selection and representative TE 30 spectra for b) thalamus (blue box), c) 
frontal cortex (red box), d) GABA-VOI [a larger basal ganglia region chosen for GABA measurements 
containing mainly thalamic tissue, but also putamen and globus pallidus (orange box)], e) globus pallidus 
(green box) and f) putamen (yellow box). Also  shown is a TE 68 MEGA-PRESS difference spectrum 
from the GABA-VOI (g).  All spectrum amplitudes are in institutional units, and plots were individually 
scaled to fill display boxes. The x-axis shows the chemical shift, or resonance frequency, in parts per 
million (ppm). The range displayed is 0.3 to 4.0 ppm. 
  
Figure 3: Significant metabolite concentration changes in mM between smelters and controls and 
significant correlations. a) Bar plot of GABA from the GABA-VOI quantified with LCModel using 
Method 2. b) Bar plot of NAA in frontal cortex, and c) correlation between NAA/tCr and cumulative Mn 
exposure for the smelters group. 
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